Navigation Links
Barr Receives Approval for Generic Version of Razadyne(R) Tablets
Date:8/28/2008

sted by Ortho McNeil Janssen in connection with Razadyne (galantamine hydrobromide), 4mg, 8mg and 12mg tablets. The Court's decision effectively ended the 30-month stay with respect to Barr's generic Razadyne tablets and Barr's generic Razadyne ER (galantamine hydrobromide), 8 mg, 16 mg and 24 mg extended release capsules.

In her ruling, District Court Judge Robinson found that the '318 patent is invalid for lack of enablement. Judge Robinson also denied Janssen's request for a Temporary Restraining Order which would have prevented Barr from marketing its product. Ortho-McNeil Neurologics, a division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., has announced that it will appeal the decision.

Razadyne tablets had annual sales of approximately $102 million for the twelve months ending June 2008, according to IMS sales data.

About Barr Pharmaceuticals, Inc.

Barr Pharmaceuticals, Inc. is a global specialty pharmaceutical company that operates in more than 30 countries worldwide and is engaged in the development, manufacture and marketing of generic and proprietary pharmaceuticals, biopharmaceuticals and active pharmaceutical ingredients. A holding company, Barr operates through its principal subsidiaries: Barr Laboratories, Inc., Duramed Pharmaceuticals, Inc. and PLIVA d.d. and its subsidiaries. The Barr Group of companies markets more than 120 generic and 27 proprietary products in the U.S. and approximately 1,025 products globally outside of the U.S. For more information, visit http://www.barrlabs.com.

Forward-Looking Statements

This communication contains "forward-looking statements" which represent the current expectations and beliefs of management of Barr Pharmaceuticals, Inc. (the "Company") concerning the proposed merger of the Company with Boron Acquisition Corp., a wholly-owned subsidiary of Teva Pharmaceutical Industries Ltd. (the "merger") and other future events a
'/>"/>

SOURCE Barr Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Instrumentation Laboratory Receives FDA Clearance to Expand the Intended Use of HemosIL(R) D-Dimer Assay
2. Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery
3. TorreyPines Therapeutics Receives NASDAQ Deficiency Notice
4. Omaxe Infrastructure & Construction Private Ltd Receives LoI for Construction of Allopathic Medical College and Associated Hospital at Saharanpur, UP With Construction Value of Approx 250 Crores
5. Caliper Life Sciences Receives $1.1 Million Task Order from the EPAs ToxCast(TM) Screening Program
6. Biotest Diagnostics Receives FDA Clearance for Full Line of Traditional Blood Bank Reagents
7. BMP Sunstone Receives Production License from the SFDA to Manufacture and Market Pediatric Multivitamin Granules in the PRC
8. XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition
9. CV Therapeutics Receives European Approval for the Brand Name Ranexa(R)
10. SGX - Lilly Merger Offer Receives Positive Opinions From Proxy Advisory Firms
11. Angiotech receives CE Mark approval of HemoStream(TM) Chronic Dialysis Catheter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2015)... ... 26, 2015 , ... Maine Standards Company, LLC is pleased ... kit. The VALIDATE® ANEMIA kit contains Ferritin, Folate, and Vitamin B12 in a ... recommended “equal delta” method for linearity testing and is liquid, ready-to-use. Simply add ...
(Date:7/24/2015)... 2015 Ryan & Maniskas, LLP that ... District Court for the Northern District of California ... purchased the common stock of Avalanche Biotechnologies, Inc. ("Avalanche" or ... and June 15, 2015, inclusive (the "Class Period"). ... the Court for appointment as a lead plaintiff of the ...
(Date:7/24/2015)... , July 24, 2015 ... equities: PDL BioPharma Inc. (NASDAQ: PDLI ), Arena ... STEM ), Northwest Biotherapeutics Inc. (NASDAQ: NWBO ... Free research report on PDL BioPharma can be accessed ... the NASDAQ Composite ended at 5,146.41, down 0.49%, the ...
(Date:7/24/2015)... , July 24, 2015 Orexigen Therapeutics, ... financial results for the second quarter 2015 on Thursday, ... Orexigen will provide a business update and discuss the ... at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time). ... phone by calling (800) 447-0521 (domestic) or (847) 413-3238 ...
Breaking Biology Technology:Maine Standards Company, LLC Announces Release of VALIDATE® ANEMIA Calibration Verification / Linearity Test Kit 2Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Avalanche Biotechnologies, Inc. 2Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Avalanche Biotechnologies, Inc. 3Biotechnology Stocks in Motion -- PDL BioPharma, Arena Pharma, StemCells, Northwest Biotherapeutics, and Acorda Therapeutics 2Biotechnology Stocks in Motion -- PDL BioPharma, Arena Pharma, StemCells, Northwest Biotherapeutics, and Acorda Therapeutics 3Biotechnology Stocks in Motion -- PDL BioPharma, Arena Pharma, StemCells, Northwest Biotherapeutics, and Acorda Therapeutics 4Biotechnology Stocks in Motion -- PDL BioPharma, Arena Pharma, StemCells, Northwest Biotherapeutics, and Acorda Therapeutics 5
... financial numbers for the end of fiscal 2005 on Thursday, ... ,Revenues were $8.3 million, an 89 percent increase over the ... to multiple unit sales, repeat purchases, new product offerings and ... however, and the company posted a loss of $4.2 million, ...
... Wisconsin in the next ten years, according to a proposal ... reach the Senate for a vote this month. State Senator ... in Wisconsin that would be regulated similarly to airports. , ... to regulate private space travel in the area, receive any ...
... investors in early-stage companies has shown results in its first ... so far applied for $1.8 million of the $3 million ... figures show. But of the $3.5 million in tax credits ... ,"We knew there would be a lag on the venture ...
Cached Biology Technology:Space port could open in Sheboygan in next 10 years 2Space port could open in Sheboygan in next 10 years 3Act 255 heats up angel investment in 2005, though VC involvement lags 2Act 255 heats up angel investment in 2005, though VC involvement lags 3
(Date:7/13/2015)... OXFORD, Conn. , Jul. 13, 2015 /PRNewswire/ ... the "Company"), a biometric authentication company focused on ... it has filed provisional patent 62/188684 for ... NXT-ID achieves another new convenient and secure method ... expands new, innovative payment methods, introduced with its ...
(Date:7/8/2015)... 8, 2015 Summary Pancreatic cancer is ... most fatal, with a mortality rate of 10.9 deaths ... pancreatic cancer patients has highlighted a significant need for ... being met by the current market. A highly ... with varying molecule types and mechanisms of action, which ...
(Date:7/7/2015)... VIEW, Calif. , July 7, 2015 /PRNewswire/ ... biometrics market, Frost & Sullivan recognizes Credence ID, ... Sullivan Entrepreneurial Company of the Year Award. ... suite to aid in its mission of offering ... under-recognized populations globally. As Credence ID was formed ...
Breaking Biology News(10 mins):NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5
... Providing food security, one of the greatest challenges ... the developing world, where crop destruction by drought, disease ... risk of hunger. Scientists at the University of ... on cowpea, a protein-rich legume crop of immense importance ...
... NJ Uncover the neural communication links involved in ... it may become possible to reverse the breakdown of ... multiple sclerosis, spinal cord injuries, diabetes and cancers of ... the New Jersey Commission on Spinal Cord Injury and ...
... 14 satellites currently in orbit and the National Aeronautics ... been able to observe the Earths environment to help ... The use of remote sensing technology aids specialists ... common and deadly infectious diseases today such as Ebola, ...
Cached Biology News:UCR researchers awarded nearly $1.7M to develop improved cowpea varieties 2UCR researchers awarded nearly $1.7M to develop improved cowpea varieties 3UCR researchers awarded nearly $1.7M to develop improved cowpea varieties 4Rutgers scientist's research reveals critical knowledge about the nervous system 2NASA technology helps predict and prevent future pandemic outbreaks 2